<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43724">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02142725</url>
  </required_header>
  <id_info>
    <org_study_id>PCG-2/UCA</org_study_id>
    <secondary_id>2012-003702-27</secondary_id>
    <nct_id>NCT02142725</nct_id>
  </id_info>
  <brief_title>Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis</brief_title>
  <acronym>PROTECT-1</acronym>
  <official_title>Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 12-weeks add-on Treatment With LT 02 vs. Placebo in Patients With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two different dosing regimens of phosphatidylcholine
      versus placebo for the induction of remission in ulcerative colitis patients non-responsive
      to standard mesalamine treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of clinical remission</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with clinical improvement</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first resolution of symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of stools per week</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with urgency per week</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mucosal healing</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of histologic remission</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's global assessment at final visit</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">762</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>LT-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LT-02 0.8g four times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: LT-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LT-02 1.6g twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LT-02 Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LT-02</intervention_name>
    <description>four times per day</description>
    <arm_group_label>LT-02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LT-02</intervention_name>
    <description>two times per day</description>
    <arm_group_label>B: LT-02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>four times per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of ulcerative colitis

          -  Active ulcerative colitis disease extent ≥ 15 cm

          -  Active disease despite treatment with mesalamine

        Exclusion Criteria:

          -  Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis,
             microscopic colitis, diverticular disease associated colitis,

          -  Toxic megacolon or fulminant colitis

          -  Colon resection

          -  Evidence of infectious colitis

          -  Celiac disease

          -  Bleeding hemorrhoids

          -  History or presence of ischemic heart disease, myocardial infarction, peripheral
             arterial disease, ischemic stroke, or transient ischemic attack

          -  Any severe concomitant renal, endocrine, or psychiatric disorder

          -  Any relevant known systemic disease

          -  History of cancer in the last five years

          -  Abnormal hepatic function or liver cirrhosis

          -  Abnormal HbA1c at screening visit

          -  Patients with known hypersensitivity to soy

          -  Known intolerance/hypersensitivity to Investigational Medicinal Product (IMP)

          -  Treatment with steroids/methotrexate/Tumor necrosis
             factor-alpha-antagonists/azathioprine/ 6-mercaptopurine/anti-integrin/coumarins

          -  Treatment with other investigational drug

          -  Existing or intended pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel Dignass, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Agaplesion Markus-Krankenhaus, 1st Dept. of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralph Müller, PhD</last_name>
    <phone>+49-761-1514</phone>
    <phone_ext>101</phone_ext>
    <email>mueller@drfalkpharma.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roland Greinwald, PhD</last_name>
    <phone>+49 761 1514</phone>
    <phone_ext>0</phone_ext>
    <email>greinwald@drfalkpharma.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Agaplesion Markus-Krankenhaus, 1st Dept. of Medicine</name>
      <address>
        <city>Frankfurt a.M.</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Axel Dignass, MD</last_name>
      <phone>+49-69-9533</phone>
      <phone_ext>2201</phone_ext>
      <email>axel.dignass@fdk.info</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>May 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
